Sox10 transcription factor is expressed in schwannian and melanocytic lineages and is important in their development and can be used as a marker for corresponding tumors. In addition, it has been reported in subsets of myoepithelial/basal cell epithelial neoplasms, but its expression remains incompletely characterized. In this study, we examined Sox10 expression in 5134 human neoplasms spanning a wide spectrum of neuroectodermal, mesenchymal, lymphoid, and epithelial tumors. A new rabbit monoclonal antibody (clone EP268) and Leica Bond Max automation were used on multitumor block libraries containing 30 to 70 cases per slide. Sox10 was consistently expressed in benign Schwann cell tumors of soft tissue and the gastrointestinal tract and in metastatic melanoma and was variably present in malignant peripheral nerve sheath tumors. In contrast, Sox10 was absent in many potential mimics of nerve sheath tumors such as cellular neurothekeoma, meningioma, gastrointestinal stromal tumors, perivascular epithelioid cell tumor and a variety of fibroblastic-myofibroblastic tumors. Sox10 was virtually absent in mesenchymal tumors but occasionally seen in alveolar rhabdomyosarcoma. In epithelial tumors of soft tissue, Sox10 was expressed only in myoepitheliomas, although often absent in malignant variants. Carcinomas, other than basal cell-type breast cancers, were only rarely positive but included 6% of squamous carcinomas of head and neck and 7% of pulmonary small cell carcinomas. Furthermore, Sox10 was often focally expressed in embryonal carcinoma reflecting a primitive Sox10-positive phenotype or neuroectodermal differentiation. Expression of Sox10 in entrapped non-neoplastic Schwann cells or melanocytes in various neoplasms has to be considered in diagnosing Sox10-positive tumors. The Sox10 antibody belongs in a modern immunohistochemical panel for the diagnosis of soft tissue and epithelial tumors. *The numbers in parentheses include expression in entrapped Schwann cells. wPositive cells represent sustentacular cells or Schwann cells. PNST indicates peripheral nerve sheath tumor.
S ox10 transcription factor belongs to the Sox family of transcription factors important in the development and maintenance of melanocytes and Schwann cells. The name is derived from the homology to the HMG-box of the sex-determining gene SRY on the Y-chromosome; Sox is abbreviated from the SRY-related HMG-box. 1, 2 Sox10 is important in the development and survival of Schwann cells and related cells. 3 Losses in Sox10 function lead to type IV Waardenburg syndrome with sensoneural hearing loss, defects in the eye and hair pigment systems, and lateral displacement of the eyes (dystopia canthorum) and also cause Hirschprung disease genetic variant associated with maldevelopment of the intestinal autonomic nervous system. 4, 5 In neuroectodermal cells, Sox10 is principally expressed in melanocytes and Schwann cells. On the basis of these findings, Sox10 has been explored as a marker for schwannian and melanocytic tumors of skin and soft tissue. [6] [7] [8] [9] [10] [11] [12] [13] Subsequently, it has been recognized that Sox10 is also expressed in myoepithelial or basal cells, especially in the breast and salivary glands and in some tumors of these sites. [14] [15] [16] However, Sox10 expression is still incompletely characterized in soft tissue tumors and carcinomas, as many entities have been studied in very small numbers if at all. Increased use of minimal diagnostic specimens elevates the importance of the immunohistochemical differential diagnosis, potentially increasing the risk for misdiagnosis, if antigen patterns of tumors remain incompletely characterized. Another problem in application of Sox10 immunohistochemistry has been the lack of high-quality antibodies. Some earlier antibodies were goat derived, which makes their use more complicated, requiring species-specific detection systems.
In this study, we examined 5134 tumors for Sox10 expression and delineate its expression in neoplasia using a new rabbit monoclonal antibody. Specific areas explored here and not previously systematically studied include complete set of peripheral nerve sheath tumors and their mimics, mesenchymal tumors of the gastrointestinal (GI) tract, all types of common carcinomas, myoepitheliomas of soft tissue, skin adnexal tumors, and germ cell tumors. In addition, we describe 2 diagnostic pitfalls: reactive Schwann cell proliferation in various soft tissue tumors, and melanocytic colonization of basal cell carcinoma that yield focal Sox 10 positivity and should not be confused with Sox10-expressing tumors.
MATERIALS AND METHODS
Normal tissues and 5134 tumors, including nerve sheath, melanocytic, mesenchymal, epithelial, and lymphohematopoietic tumors, were obtained from anonymized surgical specimens. With few exceptions (single-slide cases), the sections were derived from multitumor blocks containing 30 to 70 rectangular samples each as previously described. 17 The sample size in these slides varied but was estimated to exceed the size of a single 0.6 mm 2 core by a factor of 5 to 12. The tumors were extensively characterized histologically and immunohistochemically. Antibodies used for this are listed in supplementary Table 1 (Supplemental Digital Content 1, http://links.lww.com/PAS/A261). Gliomas and related tumors were excluded from the study.
The primary rabbit monoclonal Sox10 antibody clone EP268 was obtained from Epitomics Inc. (AC-0237, Burlingame, CA) and used at a dilution of 1:250. Immunostaining was performed using the Leica Bond-Max automation and Leica Refine detection kit (Leica Biosystems, Bannockburn, IL). The approximately 3-hour protocol included in situ deparaffinization and high-pH epitope retrieval for 25 minutes and incubation with primary antibody for 30 minutes, polymer for 15 minutes, postpolymer for 15 minutes, and DAB as the chromogen for 10 minutes, followed by 5-minute hematoxylin counterstaining. Normal tissues containing nerves, salivary gland, or breast were used as positive controls. With the above parameters and automation platform, this antibody gave a strong, background-free, nuclear signal in the positive controls described above.
RESULTS

Normal Tissues
In fetal tissue (10th week) Sox10 was narrowly expressed in developing peripheral nerves, epidermal melanocytes, subsets of cells in autonomic ganglia, nerve plexuses of the intestines, and the olfactory plate (Figs. 1A-C). It was not expressed in brain, eye, and peripheral non-neural tissues. Organs such as liver, kidney, adrenal cortex, and gonads were negative.
In adult tissues, Sox10 was expressed in epidermal melanocytes, peripheral nerves, and myoepithelial cells and also some luminal cells of the sweat glands ( Fig. 1D) , breast, and salivary glands. In the prostate, Sox10 was only occasionally expressed in basal cells. Testicular germ cells showed focal expression in some cases. Normal squamous, glandular, and parenchymal epithelia, and lymphoid tissue and histiocytes were negative. Perineural invasion was highlighted in various carcinomas, on the basis of Sox10-positive components in the nerves.
Neural and Neuroectodermal Tumors
Sox10 expression in 591 neural and neuroectodermal tumors and their selected mimics are summarized in Table 1 . Sox10 was consistently expressed in peripheral and GI schwannomas, and in nerve sheath myxomas with virtually all tumor cells positive ( Figs. 2A,  B ). In cutaneous, intraneural, and diffuse neurofibromas, it labeled subpopulations of tumor cells ranging from 20% to 40% of all cells.
All 47 S100 protein-positive granular cell tumors were Sox10 positive, whereas all 6 S100 protein-negative non-neural granular cell tumors, including 2 oral lesions in infants, were negative.
Malignant peripheral nerve sheath tumors (MPNSTs), defined here as tumors arising in preexisting neurofibroma, varied in Sox10 expression. Nearly half of the cases (31/65) contained some Sox10-positive cells. However, most commonly, Sox10 expression was seen in preexisting anatomically detectable neurofibroma components ( Fig. 2) or sprinkled throughout the tumor as smaller Sox10-positive nuclei than those belonging to the high-grade MPNST component. In only 14/65 cases was Sox10 expression recognized in unequivocally malignant high-grade components, sometimes in a mosaic manner with only a portion of tumor cells being positive ( Fig. 2D ).
Great majority of metastatic melanomas (119/125, 95.2%) were Sox10 positive with nearly uniform nuclear labeling. Exceptions were 6 poorly differentiated examples that were mainly composed of sarcomatoid spindle cells. Three of these tumors were also S100 protein negative, and 4 were negative for both HMB45 and MelanA. Because 3 other Sox10-positive melanomas were S100 protein negative, Sox10 and S100 protein were equally sensitive for metastatic melanoma in this study. One of the Sox10-negative metastatic melanomas was positive for BRAF V600E mutation similar to the corresponding primary tumor supporting the diagnosis of melanoma. All but 1 desmoplastic melanoma were also Sox10 positive, and the immunostain often highlighted a trabecular growth pattern (Fig. 3A) .
The principal cells of paragangliomas and neuroblastomas were Sox10 negative. However, sustentacular cells, present in a majority of paragangliomas, were positive ( Fig. 3B) . A somewhat similar Sox10-positive population was also present in many olfactory neuroblastomas, but the principal tumor cells were negative (Fig. 3C ). The schwannian stromal elements variably present in differentiating neuroblastomas were also Sox10 positive ( Fig. 3D ).
Mesenchymal Tumors
Sox10 expression in 1645 mesenchymal non-neurogenic tumors is summarized in Table 2 . Among non-nerve sheath tumors, alveolar rhabdomyosarcoma was 1 of the only exceptions showing positive tumor cells (2/27, Fig. 4 ). Two S100-positive tumors classified as ossifying fibromyxoid tumors were also positive. Fibroblastic-myofibroblastic tumors such as nodular fasciitis, benign fibrous histiocytoma and its variants, solitary fibrous tumor/hemangiopericytoma of the peripheral soft tissues and intracranial space, and undifferentiated pleomorphic sarcomas were always negative for Sox10. Mimics of nerve sheath tumors, such as cellular neurothekeomas, fibrous hamartomas of infancy, and meningiomas, were negative.
Lipomatous, smooth muscle, glomus/perivascular cell tumors, and other sarcomas studied were consistently negative. However, synovial sarcomas and glomus tumors often showed a small number (< 5%) of Sox10-positive nuclei that were small and likely represented entrapped neural (schwannian) elements.
All 177 lymphomas studied were negative, including large B-cell (n = 50), small B-lymphocytic (n = 32), follicular (n = 30), and miscellaneous T-cell lymphomas including large cell anaplastic lymphomas (n = 65). Also negative were 5 cases of Langerhans cell histocytosis.
Epithelial Neoplasms
Sox10 expression in 2716 epithelial neoplasms is summarized in Table 3 . Sox10 was prominently expressed in pleomorphic adenomas/mixed tumors of the salivary gland with a majority of tumor cells positive. This included positivity in ductal and solid epithelioid elements as well as chondroid components. In cutaneous and soft tissue myoepitheliomas/mixed tumors, the expression was variable. Nevertheless, 28/34 nonmalignant cases were positive. However, malignant myoepitheliomas were less frequently (6/20) positive. Examples with epithelioid cells in a myxoid stroma and those composed of spindled cells were strongly positive ( Fig. 5 ). For comparison, these malignant tumors expressed other myoepithelial markers as follows: keratins AE1/AE3 (17/20), S100 protein (10/ 20), GFAP (7/20), p63 (5/20) .
Skin adnexal neoplasms related to sweat glands had variable expression. Whereas cylindromas (including cases from patients with cylindromatosis of the scalp) and eccrine spiradenomas were uniformly Sox10 positive, hidradenomas (eccrine acrospiromas) were usually negative. Ectopic hamartomatous thymoma (branchial anlage mixed tumor) showed focal Sox10 expression in epithelial cords, but the spindle cell components were negative.
Of ductal carcinomas of the breast, 57/486 (12%) expressed Sox10, typically in all tumor cells ( Fig. 6A ), but in 3 cases <50% of the tumor cells were positive. These tumors were high grade, and the majority (60%) were ER-negative or had low ER expression (< 5% of tumor cells). A majority of Sox10-positive ductal carcinomas expressed CK5/6 (69%) or Trim29 (71%) at least focally, consistent with a basal cell type. None of the lobular carcinomas were positive. In addition, ducts with in situ carcinoma were typically bordered by Sox10-positive myoepithelial cells. Sox10 expression was rare in other carcinomas. However, it was detected in occasional squamous cell carcinomas of the head and neck and lungs, as well as in pulmonary small cell carcinomas (Fig. 6B ). The only pulmonary adenocarcinoma showing a small number of positive tumor cells was a well-differentiated fetal adenocarcinoma in a 35-year-old man that had glands with subnuclear vacuolization somewhat reminiscent of secretory endometrium (Fig. 6C) .
In embryonal carcinomas of testis, a subpopulation of tumor cells (< 10%) were Sox10 positive in 8/23 cases. This included positivity inside and in the lining element of the embryoid bodies (Fig. 6D ). Among teratomatous elements, squamous and glandular epithelia showed rare, focal positivity. All seminoma and choriocarcinoma components were negative.
Scattered Non-neoplastic Sox10-positive Cells in Nonexpressing Tumors
Scattered Sox10-positive perivascular cells, presumably Schwann cells, were detected in some but not all desmoid tumors (Fig. 7A ) and synovial sarcomas. In addition, Sox10-positive melanocytes (also positive for MelanA) were variably present around and inside the cellular nests of basal cell carcinoma (Fig. 7B ). Many but not all glomus tumors also contained Sox10-positive elements representing Schwann cells. Sox10 did not label the S100 protein-positive dendritic histiocytes variably present in most malignant neoplasms.
DISCUSSION
In this study, we examined Sox10 expression with a new rabbit monoclonal antibody offering an excellent signal quality with minimal, if any, background. Two major groups of tumors emerged that were nearly consistently Sox10 positive and were strong diagnostic targets: nerve sheath and melanocytic neoplasms among mesenchymal/ neuroectodermal tumors, and myoepithelial or basal cellrelated neoplasms among epithelial neoplasms.
Sox10 transcription factor is known to be important in the development and maintenance of the peripheral nervous system, and it is strongly expressed in Schwann cells. 6, 7 In this study, benign nerve sheath tumors such as schwannomas, neurofibromas, granular cell tumors, and nerve sheath myxomas were strongly positive with rare exceptions. It is possible that technically insufficient or antigenically poorly preserved samples played a role in the isolated negative examples. These observations confirm previous studies based on smaller series of cases. 6, 12 Because nearly all other mesenchymal tumors were negative, Sox10 helps to differentiate schwannian neoplasms from a variety of other entities. In the intracranial space, distinction of schwannoma or neurofibroma from meningioma is greatly assisted, as up to 20% to 30% of meningiomas may express S100 protein. 18 In the GI tract, Sox10 detects GI schwannomas and distinguishes them from GI stromal tumors that are occasionally S100 protein positive. Distinction of nerve sheath myxoma from the nonschwannian neurothekeomas is aided by Sox10 immunohistochemistry as previously suggested. 9 Sox10 negativity of S100 protein-positive tumors such as ossifying fibromyxoid tumor argues against their schwannian or myoepithelial derivation. Neurofibromas are composed of a heterogenous admixture of cells, with Schwann cells and CD34-positive fibroblasts being the primary components. Neurofibromas, in general, differ from schwannomas in that they contain a much smaller proportion of Schwann cells, as clearly shown by the percentage of Sox10-positive cells. This is in strong contrast with many mesenchymal tumors, such as fibrous histiocytoma variants and dermatofibrosarcoma protuberans, among which not a single Sox10-positive case was found in this study. However, certain variants with melanocyte-like components, such as pigmented dermatofibrosarcoma protuberans, could be focally positive but such cases were not included in this study.
MPNSTs are a more difficult diagnostic problem even with immunohistochemistry, because the majority of high-grade examples are negative for S100 protein. 19 Similarly, they are also often negative for Sox10, necessitating additional clinicopathologic correlation such as tumor location in a nerve trunk or origin from neurofibroma or association with neurofibromatosis 1. On the basis of our observations, it seems likely that Sox10positive cells in MPNST often are entrapped Schwann cells or residual Schwann cells from a preexisting neurofibroma. This is supported by the observation that the Sox10-positive cells often have small nonatypical nuclei.
Metastatic malignant melanoma and desmoplastic melanoma involving skin or soft tissue and sinonasal melanomas nearly always retain Sox10 expression, so Sox10 is an excellent positive marker for most melanomas. However, there are rare undifferentiated or "dedifferentiated" melanoma metastases that do not express Sox10, S100 protein, or melanoma-specific markers, so that their specific identification may be difficult. In some cases, additional sampling for more differentiated components, or BRAF V600E mutation analysis, could FIGURE 5 . Two examples of Sox10-positive malignant myoepitheliomas with the corresponding hematoxylin and eosin stain. A, An example composed of epithelioid cells in myxoid matrix arranged in a trabecular pattern (this tumor was positive for keratins and S100 protein only). B, A sarcomatoid example with a spindle cell pattern (tumor was also positive for keratins, S100 protein, GFAP, and p63). be helpful. 20 Nevertheless, the specificity of this molecular genetic test is not certain, as examples of MPNST have been reported that carry this mutation. 21 Because Sox10 is equally expressed in benign nevi, it cannot be used to distinguish benign and malignant melanocytic lesions. 6, 7, 9 Entities that can enter into differential diagnosis of nerve sheath tumor, melanoma, or clear cell sarcoma on the basis of their positivity for S100 protein include low-grade sinonasal sarcoma with neural and myoid features. 22 HMB45 or MelanA positivity is typical of perivascular epithelioid cell tumor, which often raises the differential diagnosis of a melanocytic neoplasm. As all these tumors were Sox10 negative in our study, Sox10 is helpful in their distinction from nerve sheath and melanocytic neoplasms.
Whereas early studies suggested that all carcinomas are Sox10 negative, 6 subsequent studies pointed out that a subset of breast cancer with basal cell-type features can express Sox10. 13, 15 In our study, we found that 12% of ductal carcinomas are strongly Sox10 positive, and these tumors often had focal positivity for basal cell markers such as keratins 5/6 and Trim29. We also found that lobular carcinomas are invariably Sox10 negative. In addition, other basal cell-type carcinomas, such as adenoid cystic carcinoma of the salivary gland, are also usually Sox10 positive. 14 Other carcinomas were only rarely Sox10 positive. Such examples include a small percentage (< 10%) of squamous cell carcinomas of the head and neck, occasional small cell carcinomas, and rare pulmonary adenocarcinomas. However, other common carcinomas, such as colorectal, pulmonary, pancreatic, prostatic, and urothelial carcinomas, were not found to be Sox10 positive in this study, indicating high basal cell/myoepithelial cell specificity for Sox10. Because Sox10 is generally so narrowly expressed in carcinomas but consistently present in nerves, it could be useful in pinpointing perineural invasion in the prostate and other anatomic sites.
Embryonal carcinomas were among rare carcinomas that often contained Sox10-positive elements. Such components could be analogous to Sox10 expression in early embryogenesis or possibly reflect early neurogenic differentiation.
Among non-nerve sheath soft tissue tumors, mixed tumors and myoepitheliomas were typically Sox10 positive. Sox10 expression was also consistently prominent in pleomorphic adenomas of the salivary gland and was also expressed in a great majority of cutaneous mixed tumors and myoepitheliomas. Furthermore, Sox10 aided in the identification of myoepitheliomas among potential tumor mimics such as extraskeletal myxoid chondrosarcoma, ossifying fibromyxoid tumor, and chordoma. Occasional Sox10-positive ossifying fibromyxoid tumors will need further characterization, as they might in fact represent myoepitheliomas. This could also be suspected on the basis of the fact that many investigators have included keratin-positive cases under this diagnosis. 23 Because malignant myoepithelioma is often Sox10 negative, the use of other myoepithelial markers, such as keratins, GFAP, p63, SMA, and calponin, is necessary in proper identification. These markers can also be useful in separating spindled myoepitheliomas and nerve sheath tumors, although some entities have overlapping expression patterns for some of these markers.
Skin adnexal tumors have divergent patterns of Sox10 expression. Whereas cylindromas and eccrine spiradenomas are uniformly positive, expression seems rare in hidradenomas (eccrine acrospiromas). The potential application of Sox10 in the accurate subclassification of skin adnexal neoplasm should be validated in a larger study.
Even if Sox10 is highly specific for Schwann cells, melanocytes, and myoepithelial cells and therefore an excellent marker for tumors with these types of differentiation, its expression in non-neoplastic elements can sometimes be potentially confounding. Examples of this include Sox10-positive melanocytes colonizing basal cell carcinomas and some other skin adnexal tumors; these cells have been shown positive for other melanoma markers. 24 In addition, Sox10 immunostain detects Schwann cell proliferation in tumors such as synovial sarcoma, glomus tumor, and desmoid fibromatosis. However, such Sox10 expression is always seen in a minority of cells in those settings and should not lead to confusion with nerve sheath or melanocytic neoplasms. The problem of non-neoplastic positive cells is much smaller with Sox10 than with S100 protein, as the S100 protein-positive antigen-presenting cells are nearly ubiquitous and sometimes prominently expressed in tumors prompting one to potentially assess such tumors as focally S100 protein positive.
This study was performed using slides from multitumor blocks so that the sample size was smaller than typically seen in resection specimens but larger than that in some needle biopsies and 5 to 12 times larger than present in a single 0.6 mm 2 core in tissue microarrays. Nevertheless, this could result in failed detection of very focal immunostaining. However, the results of nerve sheath and melanocytic tumors compare well with the data in previous series. 6, 9, 11 In summary, we analyzed 5134 tumors for Sox10 expression and conclude that it is fairly specific for schwannian, melanocytic, and myoepithelial/basal cell epithelial neoplasms. A new rabbit monoclonal Sox10 antibody with strong immunohistochemical labeling is an excellent marker for these tumors, as most other carcinomas, sarcomas, and all hematopoietic tumors are Sox10 negative. Table 4 lists potential morphologic mimics that show contrasting patterns of Sox10 expression, highlighting its potential diagnostic applications.
